Conducting an Ebola vaccine trial in a remote area of the Democratic Republic of the Congo: Challenges, mitigations, and lessons learned.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
12 Dec 2023
Historique:
received: 18 09 2023
revised: 14 11 2023
accepted: 14 11 2023
medline: 5 12 2023
pubmed: 23 11 2023
entrez: 22 11 2023
Statut: ppublish

Résumé

Conducting a vaccine trial in a low- and middle-income country (LMIC) can present unique challenges and lessons learned. This Ebola vaccine trial, enrolling 699 healthcare providers and frontliners and jointly set up by the University of Antwerp (Sponsor) and the University of Kinshasa (Principal Investigator (PI)), was conducted in Boende, a remote city in the Democratic Republic of the Congo (DRC), between December 2019 and October 2022 (ClinicalTrials.gov: NCT04186000). While being bound by strict ICH-GCP and international funder regulations, this trial, exemplary for being a public-private partnership, required collaboration between several international stakeholders (e.g., two universities, a pharmaceutical company, and a clinical research organization), local communities and government agencies. Here we address several logistical and administrative challenges, cultural differences, language barriers and regulatory, political, and ethical considerations over the trial's 2.5-year duration, while tailoring and adapting the study to the specific local context. Lessons learned include the importance of clear communication with participants in all phases of the study, but also within the study team and among different stakeholders. Challenges, mitigations, and lessons learned are presented in nine categories (e.g., safety management; trial documentation, tools, and materials; communication, staff training and community engagement/sensitization; financial and administrative hurdles; and more). Ultimately, to reach the successful end of the vaccine trial in this remote Ebola endemic area in the DRC, careful planning, collaboration, and great flexibility and adaptability was often required from all involved partners. Despite the encountered challenges, the vaccine trial discussed in this paper was able to obtain high participant retention rates (i.e., 92% of participants completed the study). We hope that other international teams aspiring to conduct similar trials in remote areas of LMICs can learn from the way our challenges were addressed, mitigations developed, and lessons were learned.

Identifiants

pubmed: 37993355
pii: S0264-410X(23)01363-4
doi: 10.1016/j.vaccine.2023.11.030
pii:
doi:

Substances chimiques

Ebola Vaccines 0

Banques de données

ClinicalTrials.gov
['NCT04186000']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7587-7597

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Ynke Larivière (Y)

Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium; Global Health Institute, Department of Family Medicine and Population Health, University of Antwerp, Wilrijk, Belgium.

Trésor Zola Matuvanga (TZ)

Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium; Global Health Institute, Department of Family Medicine and Population Health, University of Antwerp, Wilrijk, Belgium; Tropical Medicine Department, University of Kinshasa, Kinshasa, Democratic Republic of the Congo, The. Electronic address: zola.matuvanga@unikin.ac.cd.

Gwen Lemey (G)

Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium; Global Health Institute, Department of Family Medicine and Population Health, University of Antwerp, Wilrijk, Belgium.

Bernard Isekah Osang'ir (BI)

Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium; Global Health Institute, Department of Family Medicine and Population Health, University of Antwerp, Wilrijk, Belgium.

Paul Peter Vermeiren (PP)

Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium; Global Health Institute, Department of Family Medicine and Population Health, University of Antwerp, Wilrijk, Belgium.

Solange Milolo (S)

Tropical Medicine Department, University of Kinshasa, Kinshasa, Democratic Republic of the Congo, The.

Rachel Meta (R)

Tropical Medicine Department, University of Kinshasa, Kinshasa, Democratic Republic of the Congo, The.

Primo Kimbulu (P)

Tropical Medicine Department, University of Kinshasa, Kinshasa, Democratic Republic of the Congo, The.

Emmanuel Esanga (E)

Division Provinciale de la Santé de la Tshuapa, Democratic Republic of the Congo, The.

Junior Matangila (J)

Tropical Medicine Department, University of Kinshasa, Kinshasa, Democratic Republic of the Congo, The.

Jean-Pierre Van Geertruyden (JP)

Global Health Institute, Department of Family Medicine and Population Health, University of Antwerp, Wilrijk, Belgium.

Pierre Van Damme (P)

Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.

Vivi Maketa (V)

Tropical Medicine Department, University of Kinshasa, Kinshasa, Democratic Republic of the Congo, The.

Hypolite Muhindo-Mavoko (H)

Tropical Medicine Department, University of Kinshasa, Kinshasa, Democratic Republic of the Congo, The.

Patrick Mitashi (P)

Tropical Medicine Department, University of Kinshasa, Kinshasa, Democratic Republic of the Congo, The.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH